---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-082855"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:10:03.432126+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine cuts 20% of workforce after FDA complete response letter for bitopertin

## Summary
- Restructuring plan approved Feb 26, 2026, reducing workforce by ~20%.
- FDA issued complete response letter Feb 13, 2026 for bitopertin NDA in erythropoietic protoporphyria and X-linked protoporphyria.
- Expected aggregate charges of ~$2.0 million, primarily severance, recorded in Q1 2026.
- Implementation expected to be completed in Q2 2026; reductions focused on commercial and support functions.

## SEC filing metadata
- accession: 0001193125-26-082855
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312526082855/0001193125-26-082855-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312526082855/iron-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-082855
- JSON: https://secwatch.observer/filing/0001193125-26-082855.json
- Plain text: https://secwatch.observer/filing/0001193125-26-082855.txt

## Source-grounded claims
- claim_id: 81259e46f7f49ba9547a648780db648fe823a648
  claim: Disc Medicine, Inc. announced a restructuring with charges of approximately $2.0 million affecting commercial functions and certain supporting functions (approximately 20%).
  evidence_excerpt: Company expects to complete the implementation of the Restructuring Plan in the second quarter of 2026. The Company expects that it will incur aggregate charges of approximately $2.0 million in connection with the Restructuring Plan, consisting primarily of severance costs, which will be recorded primarily in the first quarter of 2026. The costs that the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312526082855/0001193125-26-082855-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.